Intelligent Bio Solutions Inc. · NASDAQ:INBS
Intelligent Bio Solutions — Investor Presentation (December 2024)
23 slides from Intelligent Bio Solutions's investor presentation, Dec 3, 2024
Slide 1: Intelligent Bio Solutions: Pioneering Pain-free Solutions
INTELLIGENT BIO SOLUTIONS Pioneering Pain-free Solutions Transforming testing with non-invasive, cost-effective, reliable solutions. NASDAQ: INBS | December 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended [the "Securities Act’), Section 2IE of the Securities Exchange Act 0f 1934 {the "Exchange Act’), the Private Securities L
Slide 3: Company Overview
Company Overview DSR-Plus Readers installed across customer sites 1000+ Global active customers with an estimated total of 1.4m employees 400+ 510(k) submission planned Q4, 2024 FDA Product launch planned H1, 2025 USA NASDAQ: INBS Company Name Intelligent Bio Solutions Inc. Exchange / Ticker Nasdaq:
Slide 4: ie a 3) c © = iL
ie a 3) c © = iL
Slide 5: Revenue Growth
Revenue Growth $350 $3 $3.00 2024 fiscal year $250 revenue saw a 148% increase, g 200 compared to 2 S156" $160" the same period $150 the prior year. $100 $050 $0.00 FY 2022 FY 2023, Fy 2024 * The pro forma amounts as reported in "Pro-Forma Results of Operations” in Notes Sin the INBS Annual Reports
Slide 6: We are a medical company delivering intelligent, rapid, non-invasive solutions
We are a medical compa delivering intelligent, rapid, non-invas ealinet solutions. Our mission is to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Slide 7: Simpler Drug Testing
Simpler Dru Testing Intelligent Fingerp! g System is revo
Slide 8: How it Works
How it Works Drug Metabolites Our bodies metabolize substances into detectable chemicals (metabolites) in blood, urine, saliva, and sweat. NASDAG: INBS. Sweat Detection The Intelligent Fingerprinting System detects recent drug misuse by screening metabolites in sweat from fingerprints. Detection Win
Slide 9: Steps to Simpler Drug Testing
3 Steps to Simpler Drug Testing h fing: the je into the D 10 minutes the DSR-Plus
Slide 10: Reduce Risk
as Reduce Risk Aim to identify current impairment rather than past use with a detection window. of only 16 hours. RA van Expand Testing Capabilities Conduct screening at any time and location using a compact and portable system. Respect Dignity & Privacy Preserve employee dignity with quick, non-inv
Slide 11: Intelligent Fingerprinting Platform vs Other Drug Testing Standards
Intelligent Fingerprinting Platform vs Other Drug Testing Standards Window of Detection Typical Time for Results Typical Time of Test" Specialist / Training Required Biohazardous Directly Observed Drug Screening Cost* Urine 4 days ‘Onsite or lab (1-3 days after lab receipt) 20 mins- 4 hours + Yes Ye
Slide 12: Market Opportunity
ae ae o > ele To co 2a re) rome) oD Da =i gL en = 19) De Co =o) 29 O5 62 a & Market Opportunity
Slide 13: USA Market Potential
USA Market Potential NASDAQ: INBS Drug Screening Products Market Segment Size: $14.9 billion by 2030? CAGR: 12.1%? Key Drivers + Stringent regulations and a focus on workplace safety * Growth in substance abuse cases. + Demand for faster, non-invasive testing technologies Opportunity for Fingerprint
Slide 14: Growing Drug Consumption
Growing Drug Consumption 2022 Snapshot 228 60 million million cannabis users, representing 4% of the global adult population and making it the most used drug in the world opioid users, representing 1.2% of the global adult population. Statistics: NODC World Drug Report 2024, reporting on 2022 market
Slide 15: Drug Use in the Workplace
Drug Use in the Workplace Drug and Alcohol Testing per Industry 2021 More than 70% of those abusing alcohol or illicit drugs in the US are employed? Percentage Of New And Current Employees! Other services except public administration Accommodation and food services Arts,entertainment, and recreation
Slide 16: FDA 510(k) Clinical Studies
FDA 510(k) Clinical Studies Pharmacokinetic (PK) & Method Comparison Study PK STUDY Number of Subjects 30 yrs Compare the levels of opiates detected in fingerprint sweat with those found in blood, oral fluid, ys and urine samples following the medically supervised administration of codeine. Results
Slide 17: Timeline (PK Study)
Timeline (PK Study) Biological Fluid Sampling -12 hours -6 hours Ohours 6 hours @ + t +—-@00000000 60 00:0 000000 ________@—____ Urine Drug Screen Urine sampling was taken prior to the initial codeine dose and ad libitum thereafter. NASDAQ: INBS Codeine Administered The Intelligent Fingerprinting Sy
Slide 18: Results (PK Study)
Results (PK Study) Average Codeine Values in Whole Blood, Oral Fluid and Fingerprint Sweat* 160 100 ~*-Whole Blood oral Fi 90 10 ral Fluid “2 Fingerprint Sweat z 2 2 : 2 3 3 8 § 2 2 20 2 8 6 8 2 uw Ww i 2 2 2 Nominal Time from intial Codeine Dose, hours NASDAQ: INBS “Urine results are not included i
Slide 19: M9) re (0) E fe) a) 1) =) ©) is fe) fe} ie) o
M9) re (0) E fe) a) 1) =) ©) 9 2 is 3 fe) fe} ie) o o Bz S Oo o + OQ fe} t
Slide 20: Product Footprint | 400+ Active Accounts
Product Footprint | 400+ Active Accounts Intelligent Fingerprinting Drug Screening System 9 9 99 %o9 9 \) 9 9 @ currently setting 9 @ Pinned Launch ev 2024 @ Pienned Launch cy 2025 NASDAQ: INBS 20
Slide 21: Customer Testimonials
Customer Testimonials Auctus Management Group Robinson Brothers “From our initial cost analysis, we see fingerprint-based drug screening as highly cost- effective. We estimate that Intelligent Fingerprinting will allow us to conduct the same volume of tests at around half the cost.” “By using finger
Slide 22: Summary
Summary Wa Increased revenue and growth, utilizing the Razor/Razor-blade model. NASDAQ: INBS. Large growing customer base with 1000+ installed readers and 400+ active customers. g Multiple milestones completed as we progress toward planned Q4, 2024 FDA submission. @ Rapid, non-invasive, cost-effecti
Slide 23: Thank You
Thank You www.ibs.inc | info@ibs.inc
Intelligent Bio Solutions — Investor Presentation (December 2024) on 6ix